Why is $SMMT moving today? · SEC 8-K archive

$SMMT SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $SMMT: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $SMMT filing catalyst

Why did $SMMT trigger an AI stock catalyst alert?

$SMMT triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.0/10). Headline: Summit Therapeutics Files Prospectus Supplement Under S-3 Shelf. Key points: - Form 8-K Item 8.01 filed regarding prospectus supplement to Form S-3 shelf registration - Legal opinion of Baker & Hostetler LLP filed regarding legality of common stock issuance - Indicates potential future equity financing and share dilution

How did $SMMT stock react after the SEC filing?

After the SEC 8-K for $SMMT, observed market reaction: T0 price $16.17. Past moves do not guarantee future results.

Where can I get real-time $SMMT SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $SMMT via Telegram and the VIP Web Terminal from €10/month.

$SMMT – Summit Therapeutics Files Prospectus Supplement Under S-3 Shelf

Summit Therapeutics Inc.
· SEC 8-K · All $SMMT

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (-1.0 / 10)
  • Form 8-K Item 8.01 filed regarding prospectus supplement to Form S-3 shelf registration
  • Legal opinion of Baker & Hostetler LLP filed regarding legality of common stock issuance
  • Indicates potential future equity financing and share dilution

$SMMT – Summit Therapeutics Q3 Net Loss Narrows to $208.4M (-$0.26/sh), Advances Ivonescimab Trials

Summit Therapeutics Inc.
· SEC 8-K · All $SMMT

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.0 / 10)
  • Q3 GAAP net loss narrowed to $208.4 million or $(0.26) per share compared to $(231.8) million or $(0.31) per share in Q3 prior year.
  • GAAP operating expenses decreased to $214.6 million from $234.2 million, driven by lower G&A costs.
  • Clinical trials for Ivonescimab continue expansion into bladder and kidney cancer programs.